Q2 2024 Embla Medical hf Earnings Call Transcript
Good morning, and welcome to the Embla Medical conference call where we will review second quarter results for 2024. My name is Sveinn Solvason, President and CEO of Embla Medical, joining me today is our Chief Financial Officer, Arna Sveinsdottir; Embla Medical's new Head of Investor Relations, Klaus Sindahl is also with us today joining remotely from Copenhagen.
Today I will discuss the financial performance and progress we've made during the second half of 2024, the presentation should take roughly 10 to 15 minutes after which there will be an opportunity to ask questions during a Q&A session.
And if you turn to the next slide, please. We delivered our highest ever quarterly sales in the second quarter. Sales amounted to $217 million and organic growth was 6% in local currency, growth was 9% when including acquisitions. Sales growth for the second quarter was driven by the Prosthetics & Neuro Orthotics and strong contribution from our Patient Care segment. In our Bracing & Supports business delivered more modest
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |